Key result
Phorbol-12-myristate-13-acetate (PMA) strongly enhanced the amplitude of Cav3.2 channel currents approximately 3-fold via activation of oocyte PKC.
Population
Xenopus oocytes with reconstituted Cav3.2 T-type Ca2+ channels
Comparison
Phorbol-12-myristate-13-acetate (PMA) vs 4alpha-PMA or preincubation with PKC inhibitors
Design
Preclinical
Authors
Loading...
No clinical implications yet; leaves open PKC effects on native cardiac Cav3.2 function.
Effect estimate: approximately 3-fold enhancement
PMA upregulates Cav3.2 channel activity via activation of protein kinase C in a Xenopus oocyte model.
Park et al. (2003) studied this question. Phorbol-12-myristate-13-acetate (PMA) vs. 4alpha-PMA / PKC inhibitors was evaluated on Amplitude of Cav3.2 channel currents (approximately 3-fold enhancement). Phorbol-12-myristate-13-acetate (PMA) strongly enhanced the amplitude of Cav3.2 channel currents approximately 3-fold via activation of oocyte PKC.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: